ENYO Pharma ("ENYO"), a clinical-stage biopharmaceutical company developing innovative therapies for kidney diseases, today ...
Researchers have found in a new study that in non-diabetic patients with advanced chronic kidney disease, combined therapy ...
Everyday Health on MSN
Why are minorities less likely to be prescribed GLP-1s?
Black and Latino people are less likely than white people to be prescribed GLP-1s for diabetes. Here's what studies reveal.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback